Underlining the strategic direction of solidifying its position as a leading pan-Asian provider of scientific instrumentation, DKSH Business Unit Technology has exclusively partnered with Proveris Scientific Corporation. As part of the agreement, DKSH will obtain exclusive distribution rights of testing solutions to advance the science of nasal and inhaled drug delivery in Malaysia and Thailand.
Media release
Thailand, November 30, 2020 – DKSH Business Unit Technology and Proveris Scientific Corporation have signed an exclusive distribution agreement to promote testing solutions that drive forth the science of nasal and inhaled drug delivery in Thailand and Malaysia.
Understanding the challenges faced by manufacturers of Orally Inhaled and Nasal Drug Products (OINDPs), Proveris Scientific Corporation's measurement systems, advanced technologies and laboratory services enable customers to successfully develop and bring their products to market. Its worldwide customer base includes the top innovator and generic pharmaceutical companies, device manufacturers and regulatory agencies. Committed to quality, its products are manufactured in conformance with ISO 9001 quality guidelines and processes. Its measurement systems are certified to the ISO 9001:2015 standard by TUV Rheinland of North America.
Ben Okorodudu, Vice President, Sales, Proveris Scientific Corporation, stated: “We believe that the DKSH team will bring value to the customers in Thailand and Malaysia through great market coverage, service and access to our range of measurement systems and laboratory services. We look forward to a great partnership.”
Gabriela Gillot, Business Development Manager, Scientific Instrumentation, DKSH Technology, commented: “We are pleased to exclusively partner with Proveris Scientific Corporation in Thailand and Malaysia. Their innovative technologies complement our existing product portfolios, enabling us to offer integrated solutions to our customers, especially in the pharmaceutical industry. Leveraging our extensive sales coverage, channel management and unparalleled after-sales services, we are convinced that we can successfully drive market share growth.”
For further information, please contact:
Business Unit Technology
Irene Chen
Director Group Marketing
Phone +886 2 8752 7611
irene.yr.chen@dksh.com
About Proveris Scientific Corporation
Proveris Scientific Corporation advances the science of orally inhaled and nasal drug delivery products by driving new technology development for high performance spray characterization, capture, and analysis, while leveraging its expertise, experience, and core technologies. With customer success as its central motivating force, Proveris Scientific adds value to a global customer base with “complete solutions” which include product innovation, technical services, systems, consumables and educational training. Since its founding in 1995, the company has accelerated the development of top spray and aerosol drug products and has deployed its systems at more than 100 pharmaceutical development and manufacturing sites around the globe. Proveris’s systems are the industry standard and are used by the FDA, CFDA, and the pharmaceutical industry to generate submission-ready data. Proveris is certified to ISO 9001:2015 by TUV Rheinland of North America, Inc., and has more than 20 patents issued on its technology.
About DKSH
DKSH is the leading Market Expansion Services provider with a focus on Asia. The Group helps companies to grow across the Business Units Healthcare, Consumer Goods, Performance Materials and Technology. The service portfolio covers sourcing, market insights, marketing and sales, eCommerce, distribution and logistics as well as after-sales services. Publicly listed on the SIX Swiss Exchange, the Group operates in 36 markets with 33,350 specialists, generating net sales of CHF 11.6 billion in 2019. With its Swiss heritage, DKSH has been deeply rooted in Asia Pacific since 1865. The DKSH Business Unit Technology offers complete solutions for specialized industrial applications. With around 1,670 specialists, the Business Unit generated net sales of CHF 431.9 million in 2019.